Payer Perspectives on Topical Versus Oral JAK Selectivity

In "Payer Perspectives on Topical Versus Oral JAK Selectivity," Jason brings the payer's perspective to the emerging distinction between topical and oral JAK inhibitor selectivity.

Jason frames the emerging distinction between ruxolitinib and upadacitinib primarily as a cost question rather than a mechanistic one. From a payer's standpoint, having more therapeutic options creates leverage to negotiate lower net prices, which he considers central to his role managing pharmacy benefits. But clinical evidence and professional consensus, he says, ultimately determine which therapy fits which patient and when, shaping how policy gets constructed.

He estimates oral therapy running roughly eighty to ninety thousand dollars annually before rebates, compared to six to seven thousand dollars for topical treatment, a gap he finds mathematically difficult for an oral agent to close through net pricing alone. Because of that gap, he expects policy to require patients to fail a topical option before accessing an oral JAK inhibitor, acknowledging that this reflects cost management rather than any claim that topicals are clinically superior. He explicitly defers efficacy differentiation to the providers on the panel, saying he will let clinical judgment, not payer preference, guide which agent a given patient receives.

Jason's greatest concern remains the broader trajectory of specialty drug spend, which he describes as a critical, double-digit pain point across most books of business. He anticipates that once an oral agent receives full FDA approval, it will enter compendia and undergo P&T committee evaluation to determine appropriate use criteria. Throughout, his aim is ensuring appropriate use is paired with appropriate payment, rather than simply restricting access. He closes by reiterating that more available therapies ultimately benefit his negotiating position with manufacturers, even as the near-term cost differential between topical and oral options remains substantial.

Our next episode, "Inside the Pivotal Trials Shaping Vitiligo Treatment Choices," turns to Dr. Rosmarin's breakdown of how the pivotal topical and oral trials were designed.